Preparation of imidazopyridine compounds and their use as 5-HT6 receptor ligands

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73584515" target="_blank" >RIV/61989592:15110/17:73584515 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15310/17:73584515
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2017052394A1&KC=A1&FT=D&ND=3&date=20170330&DB=&locale=en_EP#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2017052394A1&KC=A1&FT=D&ND=3&date=20170330&DB=&locale=en_EP#</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Preparation of imidazopyridine compounds and their use as 5-HT6 receptor ligands
Original language description
The invention relates to novel imidazopyridine and imidazopyridine derivs. of formula I as antagonists of 5-HT6 receptors; their prepn. and use in the prevention or treatment of schizophrenia, anxiety, depression and other diseases. Compds. of formula I wherein A1 and A2 are different and are N and C; R1 is H and C1-3 alkyl; R2 is H, (un)substituted alkyl, (un)substituted 5- to 6-membered aryl, etc.; T is CH2, SO2, substituted C1-2 alkyl; R3 is 5- to 6-membered unsubstituted aryl, 8- to 10-membered biaryl, 8- to 10 -membered heteroaryl, etc.; and tautomers, stereoisomers, enantiomers, N-oxide, a pharmaceutically acceptable salts, hydrates and solvates thereof, are claimed. Example compd. II was prepd. by a general procedure using solid-phase synthesis. The invention compds. were evaluated for their 5-HT6 antagonistic activity. From the assay, it was detd. that compd. II exhibited Ki value of 120 nM.
Czech name
—
Czech description
—

Project
<a href="/en/project/LO1304" target="_blank" >LO1304: Support of suistainability of the Institute of Molecular and Translational Medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
WO 2017052394
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Mar 30, 2017
Owner name
Uniwersytet Jagiellonski; Palacky University Olomouc; Instytut Farmakologii Polskej Akademii Nauk
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)